Shield Therapeutics plc (STX) Ordinary Shares 1.5p
- Add to watchlist
- Create an alert
- This stock can be held in a
4.30p
4.40p
12.75p
£33.63 million
4.30p
4.20p
1.08p
n/a
0.15p (3.37%) Previous:
0.15p
1,959,032
n/a
30,000
Performance
Not available for this stock.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue (£m) | 13.09 | 5.50 |
Profit before tax (£m) | (32.38) | (49.43) |
Adjusted EPS (p): | (5.00) | (21.00) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Shield Therapeutics iron deficiency treatment approved in Canada
27 August 2024 12:28
-
Shield Therapeutics net sales grow in Q2, CEO stands down
24 July 2024 09:15
-
Shield Therapeutics reports strong US progress
7 December 2023 13:11
-
Hardman & Co Research on Shield Therapeutics (STX): Focusing on successful execution
11 September 2024 12:25
-
Interim results
4 September 2024 07:00
-
ACCRUFeR® Approved by Health Canada
27 August 2024 07:00
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.